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Abstract 
The objectives of this article are to discuss the process of community engagement experienced to plan and implement a pilot study of 
a pharmacist-provided MTM intervention focused on reducing the use of medications associated with falling, and to present the 
research methods that emerged from the community engagement process to evaluate the feasibility, acceptance, and preliminary 
impact  of the intervention.  Key lessons learned from the community engagement process also are presented and discussed. The 
relationship building and planning process took twelve months. The RE-AIM framework broadly guided the planning process since an 
overarching goal for the community partners was developing a program that could be implemented and sustained in the future. The 
planning phase focused on identifying research questions that were of most interest to the community partners, the population to 
study, the capacity of partners to perform activities, and process evaluation. Much of the planning phase was accomplished with 
face-to-face meetings. After all study processes, study materials, and data collection tools were developed, a focus group of older 
adults who represented the likely targets of the MTM intervention provided feedback related to the concept and process of the 
intervention. Nine key lessons were identified from the community engagement process. One key to successful community 
engagement is partners taking the time to educate each other about experiences, processes, and successes and failures. Additionally, 
partners must actively listen to each other to better understand barriers and facilitators that likely will impact the planning and 
implementation processes. Successful community engagement will be important to develop both formative and summative 
evaluation processes that will help to produce valid evidence about the effectiveness of pharmacists in modifying drug therapy and 
preventing falls as well as to promote the adoption and implementation of the intervention in other communities. 
 
 
Introduction 
One-third of people 65 years and older (older adults) and 
one-half of people 80 years and older will fall in a given year.
1
  
Nationally, it is estimated that falls will cost $55 billion in 
2020.
2
 Effective fall prevention has the potential to reduce 
serious fall-related injuries, emergency department visits, 
hospitalizations, nursing home placements, and functional 
decline.
3
 Because falling is not a normal part of aging and can 
be prevented, developing strategies to prevent falling is an 
important public health goal that involves several community 
stakeholders.
4
  
 
In Wisconsin, an Aging and Disability Resource Center (ADRC) 
is a community-based, public health organization that is a key 
stakeholder in falls prevention.  A network of ADRCs was 
created by statute in Wisconsin to complement and support 
the statewide expansion of managed long term care 
beginning in 2006.
5
 An ADRC can be a county or tribal entity, 
a multi-county consortium, a private non-profit organization, 
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or a combination of entities. ADRCs are required to provide a 
broad spectrum of services including providing information 
and assistance, prevention programing, benefit specialist 
services, long term care options counseling, and access to a 
wide array of public and private programs and services. 
Services provided by ADRCs must be available to the elderly, 
adults with developmental and/or physical disabilities, and 
adults with mental illness and/or substance use disorders. 
ADRC funding is tied to providing evidence-based 
programming, so they have an interest in research 
demonstrating the effects of programming. 
 
Since falls are caused by many different factors, effective falls 
prevention strategies are multifactorial.
4
  Reviewing 
medication is important since several therapeutic categories 
of drugs are classified as fall risk-increasing drugs (FRIDs)
6
 
because their use is associated with falling.
7-10
 On average, 
older fallers use 2.34 of these medications regularly.
6
 Current 
falls prevention guidelines suggest all fallers have their 
medications reviewed by a health care provider to identify 
medications that could be removed.
11
 Removing FRIDs has 
been shown to be effective at reducing the number of falls 
among older adults.
6,12  
 
Pharmacist- provided medication therapy management 
(MTM) for older adults using FRIDs likely is feasible and 
effective. Pharmacist-provided MTM is effective in reducing 
medication related problems among older adults mainly by 
pharmacists discussing and evaluating medications with 
patients and making recommendations to prescribers for 
medication modifications (stop, switch, or reduce the dose of 
a drug).
13-20 
One known study demonstrated that community 
pharmacists were effective, relative to controls, in reducing 
the proportion of older fallers who discontinued use of a FRID 
following a face-to-face MTM session.
21
  
 
Community-Academic Partnership 
The project described in this article is a partnership between 
community stakeholders and academic partners, both of 
whom wanted to develop and test the feasibility and other 
outcomes of a pharmacist-provided MTM program as a 
component of preventing falls in older adults. A key 
stakeholder involved in the project was the ADRC of Brown 
County (ADRCBC). Brown County is located in the northeast 
quadrant of Wisconsin, and contains the city of Green Bay. In 
2005, ADRCBC initiated and led the Safe, Active, Independent 
Living (SAIL) coalition, largely focused on falls among older 
adults. Several other community stakeholders were involved 
in the SAIL coalition including health care providers from 
inpatient and outpatient rehabilitation departments from 
local health systems, a community pharmacist, 
representatives from local higher education facilities training 
health care providers, and the Green Bay Fire Department. 
Currently, ADRCBC offers evidence-based programming on 
falls prevention including Stepping On, Keep Stepping, in-
home falls risk screens, and other classes on falls prevention 
topics.  
 
Considering the community health organizations, health care 
providers, and academics involved in this project, we initiated 
a community engagement process. Community engagement 
is defined as “the process of working collaboratively with and 
through groups of people affiliated by geographic proximity, 
special interest, or similar situations to address issues 
affecting the well-being of those people”.
22
 Stakeholders in 
the “community” include those individuals impacted by the 
health issue being addressed as well as academics, public 
health professionals, and policy makers.  In general, the goals 
of community engagement are to build trust, enlist new 
resources and allies, create better communication, and 
improve overall health outcomes as successful projects 
evolve into lasting collaborations.
22-24
 As such, successful 
engagement involves working with all stakeholders to learn 
cultures, norms, and lessons about each other and the 
collaborative process.
25
 Community engagement was a vital 
component of planning the current project to understand the 
strengths and weaknesses of partners, and to identify key 
aspects of the project such as the study questions, research 
design, and data collection procedures in order to study the 
feasibility and outcomes of a pharmacist-provided falls 
prevention MTM intervention. 
 
Objectives 
One objective of this article is to highlight the process of 
community engagement we experienced to plan and 
implement a pilot test of a pharmacist-provided MTM 
intervention, and to present the research methods that 
emerged from the community engagement process that will 
be used to evaluate the feasibility, acceptance, and 
preliminary impact of the intervention.  An additional 
objective of this article is to present important lessons we 
learned from the community engagement process that 
community stakeholders and pharmacy researchers could use 
if they implement a community engagement process to 
develop and evaluate the impact of pharmacist-provided 
services in the community. 
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Process of Community Engagement 
Relationship Building/Study Planning 
The PI for the current project (DM) initially was contacted by 
the program coordinator at ADRCBC (BM) to discuss a 
community-academic partnership to conduct research about 
activities the coalition was planning related to community 
pharmacist-provided medication management. A series of 
subsequent face-to-face meetings over six months conducted 
in Green Bay focused on several topics including 
introductions to group members, potential research ideas, 
knowledge gained from previous activities, capacity for new 
activities, comfort with the research process, and the 
feasibility of expanding activities into new areas. There were 
four core members of the planning group (DM, BM, JK, and a 
retired psychiatrist at ADRCBC). The academic partner helped 
the community partners write two grants to obtain support 
for new projects.  
 
Discussions related to planning, implementing, and evaluating 
a pharmacist-provided MTM intervention for older fallers 
became more focused about 6 months into the partnership. 
The community partners had a long term vision of connecting 
various pharmacy provider organizations in the community to 
older adults in order to provide needed services. The 
community partners were interested in developing such a 
program that could be disseminated, implemented and 
sustained in the community after any evaluation was 
complete. Based on this information, the academic partner 
(DM) adopted the RE-AIM framework to guide broadly the 
planning process.
26
 The RE-AIM framework was chosen since 
it can be useful to translate research into practice and to help 
plan public health programs and improve their chances of 
working in “real-world” settings. Additionally, the RE-AIM 
framework addresses issues related to patients who will be 
targets for a program and issues related to organizations that 
will provide the program.
26
  The planning process focused on 
various topics within and outside of the RE-AIM framework.  
 
The first topic discussed was the research questions that 
could be addressed and questions that were of most interest 
to the group. Past successes and failures related to 
medication management in older adults, the role of 
pharmacists in medication management, as well as a vision 
for the future were discussed. The group was able to list key 
questions that needed to be researched and to prioritize the 
order of the key questions. The group determined that a pilot 
study to examine the feasibility of implementing a program as 
well as show preliminary impacts of the pharmacist was a top 
priority since a pilot study was small in scale and could best 
capitalize on available resources. 
 
The next topic discussed in the planning phase was the 
patient population to study. Ultimately, the group decided to 
focus on older adults who completed the Stepping On falls 
prevention workshop. This population was targeted mainly 
due to the experience of the ADRCBC in offering and 
providing Stepping On workshops; ADRCBC began offering 
the Stepping On workshop in 2008. Stepping On is promoted 
by the Centers for Disease Control and Prevention
27
 and is an 
evidence-based, multifactorial, small-group based, 
behaviorally oriented educational program to prevent falls 
among at-risk older adults.
28
 One of the seven, two-hour 
classes that make up the Stepping On workshop focuses on 
medication education and the pharmacist in our planning 
group (JK) provided these classes in the workshop. A large-
scale evaluation showed the medication education classes to 
be ineffective at modifying drugs associated with falling.
29
 
Our group wanted to show that expanding the role of a 
pharmacist beyond the medication education class could be 
effective at modifying drug use. 
 
Next, the group focused on the capacity of each partner to 
perform various procedures associated with the research, 
and to plan how the procedures would be accomplished. 
During these discussions it was important for partners to 
learn what relationships and/or processes had been 
developed and/or could be improved to facilitate the 
development and evaluation of the current project. The goal 
was not to re-invent resources, but rather identify and 
modify, if necessary, resources that currently existed. The 
academic partner’s role during these discussions was to 
highlight how various procedures would impact the quality of 
the evidence produced from the project.   
 
Next, the group discussed the value of evaluating the 
processes to implement the procedures that were developed 
for the project. Process evaluation was important for the 
group as there was a desire to understand what would work 
and why it worked. One motivation for implementing process 
evaluation was to ensure that the project could be expanded 
to serve additional older adults in the future.  After several 
face-to-face meetings, telephone conference calls and email 
were used to refine study processes (e.g. recruitment, data 
collection), and to develop all of the study materials (e.g. 
consent forms) and data collection tools (e.g. surveys, falls 
calendars). In total, the relationship building and planning 
process took about 12 months.  
 
 
Original Research COMMUNITY ENGAGEMENT 
 
http://z.umn.edu/INNOVATIONS                      2014, Vol. 5, No. 1, Article 140                          INNOVATIONS in pharmacy   4 
 
 
 
Advisory Panel to Review Procedures and Finalize Research 
Plan 
After all study processes, study materials, and data collection 
tools were developed, we sought input into the concept and 
process of the intervention from older adults who 
represented the likely targets of the MTM intervention. We 
created an advisory panel of six people who were 65 years 
and older and completed the Stepping On workshop between 
2008 and 2010. ADRCBC mailed letters to potential advisory 
panel members informing them about the advisory panel, 
their roles and responsibilities, and information if they 
wanted to participate. Older adults wishing to participate 
were telephoned and a meeting time was established. The 
study PI (DM) and the ADRCBC’s program coordinator (BM) 
met with the advisory panel. The panel discussed the concept 
of medication management, the role of the pharmacist in 
medication management, and reviewed and commented on 
all study processes and study materials. Handwritten notes 
were used to document the discussions. 
 
The panel thought the concept of medication management 
specifically focused on medications related to falling was 
needed, would be very useful, and would augment the 
medication class that was part of the Stepping On workshop. 
A common theme from the advisory panel was that they 
viewed the pharmacist as a very important health provider 
that should be involved in their care. However, several panel 
members said they often don’t notice the pharmacist when 
they go to the pharmacy or cannot identify the pharmacist at 
their pharmacy. Often times they were afraid to ask 
questions of the pharmacist as they felt the pharmacist was 
too busy to answer their questions or they were afraid the 
pharmacist did not want to be interrupted. The panel said 
they would welcome the opportunity to have a pharmacist 
meet with them to review their medications.  Additional 
panel comments about the study processes and materials 
that resulted from the planning process were incorporated to 
develop the final study methods (i.e. processes and materials) 
that are described next.  
 
Study Methods Derived from the Community Engagement 
Process 
Study Design 
A randomized, cluster, controlled experimental design is 
being used to assess the feasibility, acceptability and 
effectiveness of a pharmacist-provided MTM intervention 
focused on reducing the use of medications associated with 
falling. The unit of randomization is a Stepping On workshop 
rather than an individual patient. We were informed that 
older adults who enroll in the Stepping On workshop often 
are friends outside of the class and likely would talk with each 
other about which experimental group they were assigned. 
Thus, to avoid any contamination of the study groups, the 
randomization unit is the Stepping On workshop. Participants 
in each workshop randomized to the intervention group 
receive an MTM session and direct feedback from a 
pharmacist regarding their medication use (as described 
below). One pharmacist at one retail pharmacy in Green Bay, 
Wisconsin provides the intervention. The MTM intervention 
is incorporated into usual practice and daily activities at the 
pharmacy via scheduled appointments. Participants 
randomized to the control group receive usual care, 
consisting of a mailed pamphlet describing medication use 
and falls. The study was approved by the Health Sciences 
Institutional Review Board at our institution. 
 
Recruitment and Randomization 
Study sampling occurs from a population of Stepping On 
workshop participants. English speaking participants, 65 years 
and older, who have fallen in the past 12 months or have a 
fear of falling, who complete at least four of the seven 
curriculum classes in the Stepping On workshop, and are 
capable of providing their own consent are eligible for the 
study. 
 
Our goal is to enroll 80 participants in this pilot study who 
complete the Stepping On workshop, with each study group 
consisting of 40 participants from workshops randomly 
assigned to each study group. The primary factor considered 
when deciding on the sample size was the number of 
Stepping On workshops that would be offered by ADRCBC 
and the likely number of older adults that would sign-up for 
each workshop. ADRCBC is coordinating nine Stepping On 
workshops throughout the year and aims to enroll 15-18 
participants in each workshop. At the last meeting of each 
workshop, two IRB-trained study recruiters who volunteer at 
ADRCBC meet with Stepping On workshop participants to 
introduce the study and answer any questions.  Each 
prospective study participant receives a packet of information 
that describes the study, outlines participation expectations, 
and asks for participation. The packet contains a consent 
form that prospective study participants must sign and 
provide to ADRCBC to enroll in the study.  
 
About 4-5 days after the last meeting of each workshop, an 
IRB-trained study recruiter, who coordinates programming at 
ADRCBC, will telephone prospective study participants who 
have not enrolled in the study to answer any questions, to 
determine their willingness to enroll, and to instruct them 
how to return the signed consent form. All consent forms 
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returned to ADRCBC are faxed to the PI at the School of 
Pharmacy.  A staggered enrollment period is planned 
corresponding to the ADRCBC Stepping On workshop 
schedule.  
 
Procedures 
Following enrollment, trained third-year student pharmacist 
telephone interviewers are assigned to each study 
participant. Only male student pharmacists will be assigned 
to male study participants based on feedback from the 
advisory panel that older males can hear male voices better 
than females. Only the student pharmacist assigned to a 
study participant will contact that study participant 
throughout the study. This decision was made based on 
feedback from the advisory panel that they preferred to not 
be contacted by several different people during the study as 
there could be uncertainty whether the contact was related 
to the study.  All telephone contacts and interviews will use a 
standardized script developed by the study team and all 
student interviewers will be blinded to study group 
assignment.    
 
The study timeline is outlined in Figure 1.  After establishing a 
time for the pre-intervention survey, the student pharmacist 
informs the project manager that a time for the pre-
intervention telephonic interview has been established. The 
project manager then mails the study participant Packet #1.  
A  cover letter in the packet thanks them for participating in 
the study, contains a reminder of the time for the pre-
intervention telephone survey, and instructs them to 
complete the pre-intervention survey form and drug 
(prescription, OTC and herbal) therapy lists so they can be 
used during the pre-intervention telephone survey.  
 
After the pre-intervention survey is completed, the project 
manager provides the name and contact information for each 
intervention group member to staff at the retail pharmacy.  
Each intervention group member will be contacted by an 
employee of the retail pharmacy to arrange a date and time 
for the MTM session with the study pharmacist. The MTM 
session will take place at the pharmacy with the study 
pharmacist, unless another location is requested by the study 
participant. After the MTM session, the study pharmacist will 
give the participant Packet #2 containing a pamphlet 
describing the role of medications in falls.
30
 The monthly falls 
calendars, and instructions to complete them, are to be used 
to document falls that study participants experience. The 
schedule grid will help remind study participants of upcoming 
interviews with the student pharmacist. The first follow-up 
telephone interview with intervention group participants will 
take place approximately six weeks after the MTM session. 
We allotted two weeks for the MTM session to have an 
impact on the medications used by the study participant. 
 
All control group participants will receive Packet #2 by mail 
after the pre-intervention survey. The first follow-up 
telephone interview with control group participants will take 
place approximately 44 days after a control group member 
was assumed to have received the pamphlet. We allotted two 
weeks for the pamphlet to have an impact on the 
medications used by a study participant. 
 
For each follow-up telephone call, the student pharmacists 
will contact study participants about 7 days before the call to 
reconfirm the time and date for the follow-up telephone call. 
During the follow-up telephone calls participants will be 
asked to refer to the falls calendar to provide information 
about falls and will be asked about current medications they 
are taking and any medication-related changes. For the 
intervention group, the study pharmacist will provide a 
follow-up telephone call 90 days after the medication 
assessment. At the end of each call a time and date for the 
next follow-up call will be established.  
 
 
The post-intervention survey  will take place approximately 6 
months after the initial MTM session by the study pharmacist 
(intervention group) or 6 months after receipt of the 
pamphlet (control group). Participants will be given $50 for 
participating in the study: $25 after pre-intervention survey 
completion and $25 for completing the entire study. 
 
Information collected during all of the telephone interviews 
will be entered by the student pharmacists into an electronic, 
web-based patient medical record (EMR) created by the 
study team. The study pharmacist also will enter information 
collected during the MTM session and the 90-day follow-up 
telephone call into the EMR. Student pharmacists and the 
study pharmacist can access each patient’s EMR, download 
the file, update the file with new information, save the file, 
and upload it back to the server.  
 
Intervention 
The one-hour MTM session with the study pharmacist will 
follow the core components of MTM.
31
 The goal of the MTM 
session is to identify and modify the use (i.e. remove drugs, 
switch drugs, and lower doses) of any FRID and provide 
education to the patient about disease management and falls 
prevention. Prior to meeting with the patient, the study 
pharmacist will access the EMR for the patient to review the 
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information collected during the pre-intervention survey. 
When the patient and the study pharmacist meet, the study 
pharmacist will conduct a medication therapy review (MTR), 
talking with the patient about the appropriateness of each 
medication (prescription, OTC, and herbal), identifying any 
adverse drug events experienced by the patient, and 
providing education to improve medication self-
management. Based on the MTR the study pharmacist will 
develop a medication-related action plan and communicate 
recommendations for medication modification to patients 
and corresponding prescribers. It is expected that the MTM 
session will take no more than 60 minutes. The study 
pharmacist will document in the EMR and follow-up on all 
recommendations made to prescribers to determine whether 
they are accepted or rejected.  
 
The study pharmacist (JK), a geriatrician with expertise in falls 
prevention (JM), a geriatric pharmacotherapy expert (RB), 
and a researcher with expertise in adult education (BM) 
worked with the PI (DM) to develop an evidence-based 
clinical algorithm for the study pharmacist to follow during 
the MTM session. The study pharmacist has extensive 
experience as a nursing home consultant and is a certified 
MTM pharmacist in Wisconsin, which includes motivational 
interviewing (MI) training. The geriatrician contributed expert 
information related to geriatric disease management and falls 
education. The geriatric pharmacotherapy expert provided 
information related to the inclusion of FRID for the MTM 
session as well as assessment and modification for FRID to 
the clinical algorithm. A total of five therapeutic categories of 
drugs (neuroleptics, benzodiazepines, anti-depressants, 
sedative/hypnotics, and antihypertensives), as well as certain 
additional drugs [cyclobenzaprine, carisoprodol, sedating 
antihistamines (e.g. hydroxyzine, meclizine, dicyclomine, 
diphenhydramine) oxybutynin, carbamazepine, 
methocarbamol, prochlorperazine, benztropine, and 
trihexiphenidyl] with good literature support showing 
association with falls among persons 65 and older are 
included in the clinical algorithm.
7-10
  
 
To be successful in modifying medication, a pharmacist must 
effectively communicate recommendations to patients 
and/or to prescribers and have the recommendations 
accepted.  The study pharmacist has extensive experience 
communicating medication recommendations to physicians 
in nursing homes. For this project, we developed a form that 
the study pharmacist will fax to prescribers to communicate 
medication recommendations. 
Student Pharmacist and Pharmacist Training 
Guided student pharmacist protocols and interview scripts 
for the pre- and post-intervention surveys and the monthly 
follow-up telephone calls were created and reviewed for 
content validity.  The protocols and scripts were used by the 
study team to train student pharmacists and will be used to 
assess fidelity to the protocols of the actual interviews 
between student pharmacists and study participants. Student 
pharmacist training consisted of a thorough review of the 
guided interview script with simulated practice and feedback. 
After a discussion about interviewing for research, each 
section of the script was reviewed with suggestions for 
handling specific scenarios (e.g. participants asking 
medication-related questions which the student pharmacists 
were not permitted to answer). Student pharmacists were 
trained to ask open-ended questions in appropriate 
situations, to ask probing questions when necessary, and 
were trained not to provide any health or medication-related 
advice if asked by study participants.  In such a situation, 
student pharmacists were trained to tell participants to ask 
their pharmacist or physician about any such questions or 
issues. After the student pharmacists had time to review the 
script and listen to an example, they participated in simulated 
practice with a study member (BM). Student pharmacists 
were trained to enter all information obtained during the 
interviews into the EMR.  
 
To facilitate pharmacist training and assessment of fidelity, a 
Falls Medication Review Session protocol was developed. The 
protocol contains checklists for the pharmacist to use in 
preparing for, conducting and completing each MTM session.  
The protocol also contains detailed checklists for the 3-month 
follow-up telephone calls, including a discussion of 
recommendations and changes. In addition to traditional 
MTM session content, the protocol purposefully incorporates 
components of the OARS framework
32
 within motivational 
interviewing including establishing rapport, using open-ended 
questions (i.e. “O”), providing affirmation and positive 
feedback and reinforcement for positive participant choices 
and behaviors (i.e. “A”), reflective listening (i.e. “R”), involving 
the participant in decision-making, , and summarizing key 
points (i.e. “S”).  
 
A 4-hour, live, training session with the pharmacist and the 
research team was conducted. The evidence-based clinical 
algorithm and Falls Medication Review Session protocol were 
reviewed in detail and the pharmacist was instructed to refer 
to them during each MTM session. Due to study-related 
outcomes, the pharmacist training also emphasized the 
importance of prioritizing participant-directed interventions, 
with the order of preference being identifying FRID use using 
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the clinical algorithm, recommending FRID modifications, 
identifying and resolving adverse drug events, and 
recommending fall reducing lifestyle management. 
Additionally, the study pharmacist was introduced to the 
web-based electronic medical record and instructed how to 
access study participants’ EMR, write to the EMR, save them, 
and upload them to the secure server. A user’s guide to using 
the web-based electronic medical record system was created 
for the pharmacist to use if needed.  
 
Process and Outcome Evaluation 
Table 1 contains a summary of the process and outcome 
evaluations that will be conducted as part of the study. All 
interactions (i.e. telephone interviews and face-to-face 
communication) between the study participants and the 
student pharmacists and the study pharmacist will be 
audiotaped. The audiotapes will be used to conduct some of 
the process evaluations. Periodic phone conversations with 
the pharmacist will be used to obtain feedback about the 
usefulness of the EMR and any barriers to providing the MTM 
sessions. The program coordinator at ADRCBC will tabulate 
Stepping On participation and we will combine this with 
enrollment data to determine accrual rates and attrition 
rates. Reasons for not enrolling in the study as well as 
dropping out of the study will be assessed. 
 
Outcome evaluation will include participant outcomes as well 
as what happens with recommendations made by the 
pharmacist. Primary outcomes include the proportion of 
study participants that stop using FRIDs and the number and 
type of FRIDs that are stopped. Secondary outcomes are 
changes in the proportion of study participants who fall and 
the number of falls in the post-intervention time period, and 
a tertiary outcome is the acceptance rate of pharmacist 
medication recommendations. Participant information will be 
collected using a 109-item pre-intervention survey and a 70-
item post-intervention survey. Both surveys contain items to 
ascertain a complete medication list (prescription, OTC, and 
herbal supplements). The purpose of the follow-up telephone 
calls is to determine the frequency and severity of any falls 
experienced by participants and to identify any changes in 
medication use since the last study contact. 
 
The use of any FRID and the quantity of FRID use in the pre-
intervention period will be assessed by the MTM pharmacist 
(intervention group) and a study clinical pharmacist (control 
group) by comparing the clinical algorithm developed for the 
study with the list of medications patients reported in the 
pre-intervention survey. The MTM pharmacist will document 
in the EMR all medication recommendations made to 
prescribers and participants as a result of the MTM session 
and whether the recommendations were accepted by 
prescribers and participants. The study clinical pharmacist will 
document in the EMR all medication recommendations for 
control group participants. Changes in the use of FRID for 
both intervention and control group study participants will be 
assessed by study staff by examining documentation in the 
EMR about changes in medication obtained from study 
participants during the follow-up telephone calls and by 
comparing names and dosages of medications participants 
reported using in the pre- and post-intervention time periods.  
 
The number of falls in the post-intervention period will be 
assessed through the use of falls calendars completed by 
study participants and follow-up telephone interviews.
36,37
  
The post-intervention survey includes items to assess 
participant satisfaction with the pharmacist (data collected by 
the trained student pharmacist)
38
 and participant satisfaction 
with the student pharmacist (data collected by a non-student, 
study staff member). 
 
Analysis 
Descriptive statistics (mean, standard deviation, frequencies) 
will be reported for all variables collected at baseline and six 
months by study group. Differences at baseline and from 
baseline and month six will be compared by study group 
using appropriate statistical tests. The descriptive statistics 
will be used to inform sample size calculations for a similar, 
larger trial. Accrual rate will be estimated by the average 
number of Stepping On workshop participants that enroll 
after each workshop and overall. The study dropout rate will 
be estimated by the number of enrolled study participants 
lost to follow-up divided by the total number of enrolled 
study participants.       
 
Lessons Learned from the Community Engagement Process 
The community engagement process is important as it can 
inform the adoption, implementation, and sustainability of 
effective, evidence-based programs in communities to better 
serve clients. The process of academic researchers and 
community-based public health organizations engaging with 
each other for the purpose of planning and conducting 
evaluations of health care service delivery models likely will 
become more common.  Table 2 contains a list of nine lessons 
we learned from the community engagement process and a 
description/examples for all nine lessons. One important 
lesson from the community engagement process was 
discussing and coming to agreement on the importance of 
including both process and outcome evaluation in the pilot 
study. It is important to note that both types of evaluation 
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were important to all community partners engaged in the 
process. There was consensus among the community 
partners that the results of the evaluations would provide 
information related to decisions that were made during the 
community engagement process and would inform a future 
larger-scale version of the pharmacist-provided intervention. 
The following paragraphs provide more details about our 
community engagement process and highlight some of the 
lessons learned during the community engagement process. 
 
An important decision from the perspective of both the 
academic and community partners is determining the 
research questions to pursue. One barrier to this decision is 
academic partners proposing to do too much, too fast, before 
completely understanding the capabilities of the community 
partners. Academic and community partners must take time 
to discuss the activities that have been tried in the past, the 
process used to implement activities, problems with the 
process, and the results of the activities, both successes and 
failures.   In the present situation, the ADRCBC had been 
working on falls prevention for a relatively long time and had 
involved other partners in the community. The Brown County 
coalition had tried many approaches to falls prevention and 
had experimented with the process and feasibility of a 
pharmacist meeting with patients and reviewing medications. 
They were ready to expand services to study the pharmacist’s 
impact on modifying FRID use.   We found face-to-face 
meetings facilitated this process. Partners need to provide 
information, ask questions, and listen to each other in order 
to identify mutually agreeable research questions. 
 
Another important issue we discussed was the research 
process and determining which research components the 
community partners were comfortable performing.  A key 
facilitator in this step was the community partners’ 
understanding of the value of good evidence to show 
program impact. Further, the community partners 
understood the relationship between research processes and 
the quality of evidence produced from the processes.  We 
worked together to identify resources and processes that 
could be used to facilitate proper execution of important 
elements of the research design, research procedures, and 
data collection.  We worked to gain consensus on who would 
perform various research activities and how those activities 
would be accomplished. Since we were doing new things, it 
was easy to reach agreement about the need to study what 
worked and did not work (i.e. process evaluation).  Further, 
one advantage of conducting a pilot study is incorporating 
process evaluation to determine what aspects of the research 
procedures and data collection are operational.  
 
ADRCBC will be coordinating the recruitment of study 
participants. We had numerous meetings, both in-person and 
via telephone, to discuss the recruitment process including 
the timing (before or after a workshop session and which 
workshop session) of recruitment, the content of the 
recruitment message, who should provide the recruitment 
message, and incorporating IRB standards into the 
recruitment process. Fortunately, ADRCBC identified two 
people, both over age 65, who volunteered to be present at 
the recruitment sessions, provide the message, and answer 
questions that potential participants may have about the 
study. Both of the recruiters were actively engaged in the 
discussions about the recruitment process. One of the 
recruiters is a retired psychiatrist who is an advocate for falls 
prevention and has first-hand experience about the role of 
medications in falling. The other is a Stepping On workshop 
leader and retired physical therapist with experience treating 
patients who had fallen. The study recruiters feel very 
confident that they will be able to address any concerns 
potential study participants have about participating in a 
study such as, sharing health care data and visiting with a 
pharmacist. The group agreed to  monitor the recruitment 
process using accrual rates as well as obtaining feedback from 
the study recruiters after each recruitment session about 
what is working and not working during the recruitment 
sessions and what concerns potential participants have about 
participating in the study. All of this  information will be used 
to improve the recruitment process.  
 
Another study component that was discussed at length was 
who will collect data from study participants and how data 
will be collected. Based on previous experience, the 
pharmacist and the other community partners knew it was 
not feasible to have the pharmacist collect patient 
information about health status, falls history, and medication 
list data (i.e. name of drug, dose, frequency, problems, etc.).  
Also, there was consensus that providing the data to the 
pharmacist before the MTM session would allow the 
pharmacist to better utilize his time with the participants. The 
community partners had experience with using health care 
professional students from local community colleges to 
collect patient health-related data using various data 
collection forms and computer software in a previous project. 
Thus, they were aware of the relative advantages and 
disadvantages of having students collect data and, generally, 
were open to the idea of using trained student pharmacists 
for this project. The pharmacist is supportive of using student 
pharmacists due to their familiarity with drugs, drug names, 
and health care in general. As part of process evaluation, we 
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will obtain participants’ reaction to the data collection 
process with the trained student pharmacists. Additionally, 
the pharmacist will assess the accuracy and completeness of 
data collected by the student pharmacists and entered into 
the EMR based on conversations he has with participants. 
Lastly, there was some concern that the number of telephone 
interviews will be burdensome for participants and that they 
will be hesitant to answer the telephone. Comments from the 
advisory panel were instrumental in finalizing the telephonic 
data collection procedures.  
 
Another issue we discussed was whether a community 
pharmacy, with a myriad of potential interruptions, is an 
appropriate scientific environment in which the pharmacist 
must follow a protocol to provide the MTM sessions and to 
document the outcomes of the sessions in a retrievable form. 
The mutual decision among the partners to audiotape the 
MTM sessions will allow us the opportunity to listen to the 
MTM sessions after they occur and determine the fidelity of 
the sessions to the clinical protocol. Any deviations from the 
protocol will be communicated back to the pharmacist for 
adjustment in future sessions. It should be noted that the 
pharmacist that is involved in the project (JK) is trained to 
provide MTM and has over 20 years of practice experience 
working in a nursing home environment communicating drug 
therapy concerns to physicians. The willingness of the 
pharmacist to participate in these aspects of the process 
evaluation demonstrates his commitment and motivation to 
participate in the study and learn how to improve the 
program. 
 
After the pilot is complete, the current plan is to expand the 
model of a pharmacist-provided MTM focused on falls 
prevention to additional counties. The expansion process will 
involve identifying and engaging with additional community 
partners and using the lessons learned from our community 
engagement process in the expanded project. We will 
continue to involve ADRCBC as we expand our model, as 
ADRCBC is an advocate for the model and the community 
engagement planning process. Our experience suggests that 
following a community engagement process is an important 
step in promoting the dissemination, implementation, and 
sustainability of pharmacist-provided patient services in the 
community.             
 
Conclusion 
Pharmacist involvement in falls prevention is an area for 
future research that could include partnerships between 
academic researchers and community partners. Successful 
community engagement will be important to develop both 
formative and summative evaluation processes that will help 
to produce valid evidence about the effectiveness of 
pharmacists in modifying drug therapy and preventing falls as 
well as promote adoption and implementation of the 
intervention in other communities. The lessons learned and 
the research methods developed through a community 
engagement process outlined and discussed in this article will 
be used to develop a similar, expanded trial to study the 
effects of community pharmacists on modifying drug therapy 
to prevent falls among older adults. 
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Table 1: Summary of Evaluation Process and Measures 
Type of 
Evaluation 
Purpose of  
Evaluation 
Data Collection  
Method 
Measures 
Process  Assess the feasibility of 
student pharmacist interviews 
 Assess the fidelity of student 
pharmacists to the interview 
protocol 
 Audit of contacts made with study 
participants 
 Audiotape of participants -student 
pharmacist interviews 
 Periodic meetings with student 
pharmacists 
 Feedback from pharmacist about 
electronic medical record 
 Number of contacts to schedule and 
complete interviews 
 Length of time to complete interview 
 Completeness of asking questions in 
interview protocol 
 Accuracy of interview information 
documented in electronic medical record 
  Assess the feasibility of 
providing the MTM session  
 Assess the fidelity of the 
pharmacist to the MTM 
protocol 
 
 Audiotape of MTM sessions 
 Periodic telephone conversations with 
pharmacist 
 Completeness of covering topics in MTM 
session protocol 
 Ease of using and completeness of 
documentation in electronic medical record 
 Length of time to complete MTM session 
 Barriers to providing MTM session 
  Assess the recruitment process  Tabulation of both Stepping On 
participants who are eligible for the 
study and Stepping On participants 
who enroll in the study 
 Audit of study completion by 
participants 
 Accural rate 
 Attrition rate 
Outcome Collect pre-intervention measures  Telephone interview with study 
participants 
 Review of patient prescription, OTC, 
and herbal medication list by clinical 
pharmacist 
 Demographics 
 Health Status 
 Geriatric Syndromes 
 Number of falls in previous six months 
 Prescription, OTC, and Herbal medication list  
 Fear of falling (the Modified Falls-Efficacy 
Scale, the Mobility Efficacy Scale, and the 
Falls Behavioral Scale)
33-35
 
 Use of FRID 
  Collect monthly follow-up 
measures 
 Assessment of pharmacist 
recommendations 
 Monthly telephone interviews with 
study participants 
 Monthly falls calendars 
 Review of patient prescription, OTC, 
and herbal medication list by clinical 
pharmacist 
 Review of pharmacist 
recommendations 
 Health Status 
 Changes in medication list 
 Number of falls 
 Use of a FRID 
 Acceptance of pharmacist recommendations 
  Collect post-intervention 
measures 
 Assessment of pharmacist 
recommendations 
 Telephone interview with study 
participants  
 Review of patient prescription, OTC, 
and herbal medication list by clinical 
pharmacist 
 Review of pharmacist 
recommendations 
 Health Status  
 Number of falls 
 Prescription, OTC, and Herbal medication list 
 Fear of falling (the Modified Falls-Efficacy 
Scale, the Mobility Efficacy Scale, and the 
Falls Behavioral Scale)
33-35
 
 Use of a FRID 
 Acceptance of pharmacist recommendations 
 Participant satisfaction with pharmacist 
 Participant satisfaction with student 
pharmacist interviewer 
 
Note: Use of FRID determined by reviewing recommendations made by the study pharmacist (treatment group) or a clinical pharmacist (control 
group). 
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Table 2: Lessons Learned from the Community Engagement Process 
 
 Description/Example 
1. Assess capabilities regarding research project Determine how comfortable partners are with conducting research. Identify 
strengths and weaknesses of partners in terms of resources available for a research 
project. 
2. Determine willingness of partners to conduct process 
evaluation  
If the partners agree to develop/implement a new process as part of the research 
project, evaluation of the process will promote identification of barriers and 
facilitators and lead to process improvement. Process evaluation may require 
additional time and resources, but it is important for implementation and 
maintenance of a program. 
3. Assess the willingness of partners to adapt and make 
changes  
Planning a research project may require partners to change the way they currently 
do things in an attempt to standardize processes. All partners have to understand 
the reasons for changes and buy into the changed process.   
4. Develop trust among partners All discussions have to be honest, complete, and show no hidden agendas. All 
partners must work together and have a common understanding of the project. 
Reviewing past discussions and rationale/motivation for decisions made is a good 
way to promote common understanding. It is vital to follow through with 
assignments/tasks.   
5. Partners must understand the history/background of 
each other related to the research project 
Establishing a timeline of each partners’ activities related to the research project is 
a good approach to promote understanding. The timeline should include success as 
well as failures. Understanding reasons for success and failures is very important as 
it helps identify the strengths and weaknesses of each partner. The timeline also 
will provide an understanding of where in program development the partnership is 
located (i.e. early stages versus modifying a long-term successful program). 
6. Assess how comfortable partners are with the research 
process 
Discussions need to occur that focus on each partner’s perceived value/need for 
research, knowledge of research, and whether partners have conducted research 
in the past. All of this information is useful in determining each partner’s comfort 
level with engaging in the research process. 
7. Promote face-to-face meetings Making time to meet face-to-face, especially at the beginning of the engagement 
process, is very important as it shows commitment to the partnership. Also, seeing 
reactions of partners to various discussion points and ideas is vital to better 
understanding the comfort level of partners as it relates to the research process 
and program development.  
8. Recognize resources that partners are committing to 
the research project 
Partners will be more willing to expend time and resources if they have a sense 
that all partners are committing an equal amount of time and resources to the 
project. Promote discussions about activities performed by each partner to 
promote better understanding among partners about resources devoted to the 
project. Be willing to consume resources to deal with any imbalances.  
9. Partners must listen carefully to each other As described in the items above, much of the community engagement process is 
sharing past experiences with projects and ideas for future projects. It is important 
that partners pay attention and actively listen to what is said and acknowledge 
successes, failures, barriers, facilitators, etc. Partners have to be careful to not 
move ahead with new ideas without acknowledging and discussing past 
experiences. Much can be learned about how to proceed by listening carefully to 
each other.   
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Figure 1: Falls Prevention MTM Study Timeline 
 
 
Initial Call and 
Packet #1 Mailing 
Pre-Intervention 
Telephone 
Interview 
 
MTM Session for 
Intervention 
Group 
 
Packet #2 Mailing 
 
Follow-up #1 
 
Follow-up 
#2-#5 
 
Post-Intervention 
Interview 
Within 5 days of 
study staff 
receiving signed 
consent, call from 
student 
pharmacist to 
participant to 
establish 
interview time. 
Mailing includes: 
cover letter, copy 
of signed consent 
form, survey and 
blank medication 
list.  
Student 
pharmacist 
conducts pre-
intervention 
survey interview 
with intervention 
and control group 
participants.  
MTM pharmacist 
conducts face-to-
face MTM session 
with each 
intervention 
group participant  
Mailed to control 
group after pre-
intervention 
survey. Given to 
intervention 
group by 
pharmacist after 
MTM session. 
Packet includes: 
drug pamphlet, 6 
falls calendars, 
blank telephone 
follow-up 
scheduling grid.  
44 days after pre-
intervention 
survey interview 
for control group. 
44 days after 
MTM session for 
the intervention 
group.  
30 days between 
follow-up calls for 
intervention and 
control group 
participants.  
Pharmacist 
conducts 
telephonic follow-
up for 
intervention 
group 104 days 
post-MTM 
session.  
30 days after 
follow-up #5 for 
control and 
intervention 
group 
participants.  
 
